Agenda
Times listed are for Eastern Daylight Savings Time.
Download a PDF version of the agenda.
DAY 1, September 28th: (11:00 AM to 4:30 PM)
| 11:00–11:10 AM | Welcome Altaf Mohammed, Ph.D., Meeting Co-Organizer, DCP/NCI Brian Cholewa, Ph.D., Meeting Co-Organizer, DCP/NCI |
| 11:10–12:00 PM | Plenary Talk NCI Division of Cancer Prevention: Overview and Research Opportunities Lori Minasian, MD., Deputy Director, DCP/NCI |
Session I: Emerging Targets, Vaccines and Immunomodulatory Agents for Cancer Prevention | |
| Co-Chairs: Nicholas Arpaia and Anda Vlad | |
| 20 minutes talk, 10 min Q&As | |
| 12:00–12:30 PM | Delivering cancer prevention vaccines into the clinic Sarah Blagdon, BSc, FRCP, Ph.D., University of Oxford |
| 12:30–1:00 PM | Programmable probiotics for personalized cancer immunotherapy and immunoprevention Nicholas Arpaia, Ph.D., Columbia University Irving Medical Center |
| 1:00–1:30 PM | Lunch |
| 1:30–2:00 PM | Immune determinants modulating cancer development in Lynch Syndrome Robert Samstein, MD., Ph.D., Icahn School of Medicine at Mount Sinai |
| 2:00–2:30 PM | Targeting the A2B Adenosine Receptor for Immunoprevenion of Pancreatic Cancer Jennifer Bailey, Ph.D., University of Texas HSC Houston |
| 2:30–3:00 PM | Manufacture of Epstein-Barr Virus Vaccine McGuire, Andrew, Ph.D., Fred Hutchinson Cancer Center |
| 3:00–3:30 PM | Break |
| 3:30–4:30 PM | Early Investigator Flash Talks |
| Co-Chairs: Altaf Mohammed and John Clifford | |
| 10 minutes talk, 5 min Q&As | |
| 3:30–3:45 PM | From TRAIL modulation to immune interception: Doradaviprone (ONC201) for colorectal cancer prevention Alexander Raufi, MD., The Warren Alpert Medical School of Brown University |
| 3:45–4:00 PM | Harnessing nutrition to enhance cancer immunotherapy Nicholas Collins, Ph.D., Weill Cornell Medicine |
| 4:00–4:15 PM | The perfect pair: Integrating drug synergy and precision nanomedicine for smarter cancer management Preshita P. Desai, B. Pharm, Ph.D., Western University of Health Sciences |
| 4:15–4:30 PM | Bladder cancer prevention Venkateshwar Madka, Ph.D., University of Oklahoma |
| Adjourn | |
DAY 2, September 29th: (11:00 AM to 5:00 PM)
Session II: Molecularly Targeted Novel Agents for Cancer Prevention and Interception | |
| Co-Chairs: Michael Buszczak and Asad Umar | |
| 20 minutes talk, 10 min Q&As | |
| 11:00–11:30 AM | Investigating novel targets for topical immunoprevention of skin cancer Clara Curiel, MD., University of Arizona |
| 11:30–12:00 PM | Mitochondria-targeted atovaquone for cancer immunoprevention Ming You, M.D., Ph.D., Houston Methodist Research Institute |
| 12:00–12:30 PM | Developing ribosome biogenesis inhibitors for the prevention of cancer Michael Buszczak, Ph.D., UT Southwestern Medical Center |
| 12:30–1:00 PM | Novel Pan-RAS inhibitors for pancreatic cancer prevention and interception Gary Piazza, Ph.D., Auburn University |
| 1:00–1:30 PM | Discovery and development of LFA-9 for CRC interception Chinthalapally V. Rao, Ph.D., University of Oklahoma |
| 1:30–2:00 PM | Lunch |
Session III: Clinically relevant alternative models for cancer prevention | |
| Co-Chairs: Brian Cholewa and Kajal Biswas | |
| 20 minutes talk, 10 min Q&As | |
| 2:00–2:30 PM | Organoids for Cancer Prevention, Interception and Treatment David Tuveson, Ph.D., Cold Spring Harbor Laboratory |
| 2:30–3:00 PM | New approach methodologies to clinical trial-in-a-dish Joseph C. Wu, MD., Ph.D., Stanford University School of Medicine |
| 3:00–3:30 PM | Microfluidics in biomedical research: lab-on-a-chip microtechnologies David Beebe, Ph.D., University of Wisconsin |
| 3:30–4:00 PM | Modeling cancer prevention and interception: Organoid platforms for preclinical vaccine and immunotherapy evaluation Yurong Song. Ph.D., Leidos |
| 4:00–5:00 PM | Meet with the NCI Program Staff
|
| Adjourn | |
DAY 3, September 30th: (11:00 AM to 4:30 PM)
Session IV: Cancer Prevention-Interception Clinical Trials | |
| Co-Chairs: Eduardo Vilar-Sanchez and Goli Samimi | |
| 20 minutes talk, 10 min Q&As | |
| 11:00–11:30 AM | Overview of DCP Supported Clinical Trials Goli Samimi, Ph.D., DCP/NCI |
| 11:30–12:00 PM | Nous 209 vaccine trial Eduardo Vilar-Sanchez, MD., Ph.D., MD Anderson Cancer Center |
| 12:00–12:30 PM | The Tamoxifen RENAISSANCE: dosing, metabolites & drug delivery Seema Khan, MD., Northwestern Feinberg School of Medicine |
| 12:30–1:00 PM | Reprogramming precancer for prevention/interception of gastric carcinogenesis James Goldenring, MD., Ph.D., AGAF |
| 1:00–1:30 PM | Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer Britt K Erickson, MD., University of Minnesota |
| 1:30–2:00 PM | Break |
Session V: Panel Discussion | |
| Biomarkers as intermediate end points for cancer prevention clinical trials | |
| Co-Chairs: Brandy Heckman-Stoddard and Goli Samimi | |
| 2:00–2:25 PM | Biomarkers as intermediate end points for oncology clinical trials Nathan Standifer, Ph.D., Vera Therapeutics, Inc. |
| 2:25–2:50 PM | Status on current intermediate end points for cancer prevention clinical trials Brandy Heckman-Stoddard, Ph.D., DCP/NCI |
| 2:50–4:30 PM | Panel Discussion |
| Closing Remarks and Adjourn Brian Cholewa, Ph.D., Meeting Co-Organizer, DCP/NCI Altaf Mohammed, Ph.D., Meeting Co-Organizer, DCP/NCI | |